Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.16 USD
Change Today +0.01 / 0.87%
Volume 23.6K
MELA On Other Exchanges
Symbol
Exchange
NASDAQ CM
Berlin
As of 8:10 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

mela sciences inc (MELA) Snapshot

Open
$1.17
Previous Close
$1.15
Day High
$1.19
Day Low
$1.15
52 Week High
03/11/15 - $4.05
52 Week Low
07/10/15 - $1.06
Market Cap
10.4M
Average Volume 10 Days
47.8K
EPS TTM
$-2.52
Shares Outstanding
9.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MELA SCIENCES INC (MELA)

Related News

No related news articles were found.

mela sciences inc (MELA) Related Businessweek News

No Related Businessweek News Found

mela sciences inc (MELA) Details

MELA Sciences, Inc., a medical device company, designs and develops software-driven technology for the early detection of skin cancer to dermatologists in the United States. It offers XTRAC, an ultraviolet light excimer laser system for the treatment of psoriasis, vitiligo, and other skin diseases; and VTRAC Excimer Lamp system for the treatment of psoriasis, vitiligo, atopic dermatitis, and leukoderma. The company also focuses on commercialization of its principal product MelaFind, a non-invasive point-of-care instrument to aid in the detection of melanoma. The company was formerly known as Electro-Optical Sciences, Inc. and changed its name MELA Sciences, Inc. in April 2010. MELA Sciences, Inc. was founded in 1989 and is based in Irvington, New York.

32 Employees
Last Reported Date: 03/30/15
Founded in 1989

mela sciences inc (MELA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $14.1K
Chief Financial Officer, Secretary and Treasu...
Total Annual Compensation: $194.0K
Compensation as of Fiscal Year 2014.

mela sciences inc (MELA) Key Developments

MELA Sciences Approves Amendment to Bylaws

On July 15, 2015, MELA Sciences, Inc. Board of Directors approved amended and restated bylaws. The amendments contained in the Fourth Amended and Restated Bylaws include the following items: The provision relating to adjournment of a stockholder meeting has been modified to state that the chairperson of a meeting of stockholders has the power to adjourn the meeting to another time, date and place, adding the clause whether or not a quorum of stockholders is present, in person or by proxy, at the meeting." The quorum requirement for a meeting of stockholders has been changed to provide that holders of one-third of the shares of stock entitled to vote at a meeting, rather than a majority, constitute a quorum for the transaction of business, unless otherwise required by applicable law. The advance notice provision for stockholder proposals has been modified to delete references to a solicitation notice that the proponent formerly was required to supply as part of the proponent's notice to with respect to a stockholder proposal. The provision regarding removal of directors has been amended to state that directors may be removed, with or without cause, by the holders of a majority of the voting power of shares entitled to vote for the election of directors. The provisions relating to the Chairperson of the Board have been clarified to state that the Chairperson of the Board, in such capacity, is not an officer of the company unless designated as an officer by the Board of Directors. The sections relating to the roles of the Chief Executive Officer and the President has been clarified to provide that the Chief Executive Officer has general management, direction and control of business and affairs, and the President is the chief operating officer of the company having such powers as assigned to the President by the Chief Executive Officer or the Board of Directors.

MELA Sciences, Inc., PhotoMedex, Inc. - M&A Call

To acquire XTRAC and VTRAC businesses from PhotoMedex, Inc

MELA Sciences, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015

MELA Sciences reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, net revenues were $81,200 against $97,638 of prior year period. Net loss was $7,272,421 or $1.12 per basic and diluted share against $7,980,596 or $1.63 per basic and diluted share for the same period a year ago. Net cash used in operating activities was $3,200,535 against $7,120,887 for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MELA:US $1.16 USD +0.01

MELA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Lucid Inc $0.75 USD -0.10
Guided Therapeutics Inc $0.11 USD +0.005
Mauna Kea Technologies €3.66 EUR -0.06
Optiscan Imaging Ltd A$0.04 AUD 0.00
Verisante Technology Inc C$0.11 CAD 0.00
View Industry Companies
 

Industry Analysis

MELA

Industry Average

Valuation MELA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.3x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MELA SCIENCES INC, please visit www.melasciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.